BTIG Rates Climb Bio (CLYM) buy, $20 Price Target
BTIG analyst Julian Harrison reiterates a buy rating on Climb Bio with a price target increased to $20, a 74.06% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated Climb Bio, Inc. ($CLYM) "buy" with a $20 price target on June 11, 2026.
Since the rating, $CLYM is up 5.0% after 1 week, up 21.1% after 1 month and down 10.0% to date (from the $10.91 close on Jun 11, 2026).
CLYM
Climb Bio, Inc.
Key Points
- BTIG has reaffirmed its buy rating on Climb Bio, Inc. with a price target increase to $20, up from a previous target of $14.05.
- The stock recently traded at $11.49, well below its 52-week high of $18.33, suggesting a potential upside.
- Analysts are optimistic, with the consensus recommendation being a strong buy and a mean target price of $27.57.
Get $CLYM trade alerts by text
We text you when insiders, Congress or big funds trade $CLYM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Climb Bio, Inc. alert may contain errors. Disclosures
BTIG Boosts Price Target for Climb Bio
BTIG analyst Julian Harrison has reiterated a buy rating on Climb Bio, Inc. (CLYM) on June 11, 2026, raising the price target to $20 from a previous target of $14.05. The stock was trading at $11.49 at the time of the rating, showing a significant potential upside as it aims to recover from its recent lows.
What Changed in BTIG's View
This adjustment marks a notable increase in BTIG's outlook for Climb Bio, as the target price moved up from $14.05 to $20. This reflects confidence in the company’s ongoing developments and potential for growth in the healthcare sector, particularly in biotechnology, where Climb Bio specializes.
Analysts Set New Price Targets
Several other analysts have provided their perspectives on Climb Bio as well. On September 8, 2026, Oppenheimer maintained an outperform rating while raising its price target from $18 to $25. Concurrently, HC Wainwright & Co. also kept a buy rating, increasing its target from $24 to $30. B. Riley Securities reiterated its buy rating with a new target of $30, up from $26. These recommendations highlight a general optimism among analysts regarding Climb Bio's prospects, culminating in a strong buy consensus and a mean price target of $27.57.
Stock Performance Insights
Climb Bio's stock currently trades below its 52-week high of $18.33, having reached a low of $1.54. This suggests that the stock may have room to grow, especially with the price target set at $20. The significant gap between current trading levels and analysts' price targets indicates potential for recovery and investor interest.
$CLYM price target
Climb Bio, Inc. daily closes and this analyst's $20 target. Not advice.
About Climb Bio
Climb Bio, Inc. is a clinical-stage biotechnology company based in Wellesley Hills, Massachusetts. The company develops therapies targeting unmet needs in immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody currently undergoing clinical trials for various B-cell mediated diseases.
What's Ahead for Climb Bio, Inc.
Investors should keep an eye on the next earnings report scheduled for November 13, 2026, as it could provide further insights into Climb Bio's performance and future outlook. As a reminder, the latest rating from BTIG reflects past holdings and may not represent the current position of the analyst or the firm.
Related Filing Alerts
Source: BTIG's rating change on $CLYM (Jun 11, 2026). Written by software, not financial advice. How we make alerts